Related Experiment Video
Updated: Jan 17, 2026
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
Chelator Optimization and Therapeutic Potential of 188Re-FAPI for FAP-Targeted Radionuclide Therapy
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
Abstract:
Fibroblast activation protein (FAP) has emerged as a highly promising molecular target for cancer theranostics, with current research prioritizing the optimization of FAP-targeted radiopharmaceutical pharmacokinetics. The development of diverse FAP inhibitor (FAPI) probes conjugated with therapeutic radionuclides has significantly advanced the field of FAP-targeted radionuclide therapy (FAP-TRT). Among available radionuclides, rhenium-188 has emerged as a particularly valuable theranostic radionuclide, offering the rare combination of economical availability, therapeutic β- emissions (E max = 2.12 MeV), and γ emissions suitable for SPECT imaging (155 keV, 15% abundance). The strategic development of 188Re-labeled FAPI compounds represents a promising approach to enhance the efficacy and clinical translation of FAP-targeted radionuclide therapy. A recent study has developed and evaluated four novel 188Re-labeled FAP inhibitors through rational structure optimization, which provided a cost-effective viable alternative to established therapeutic radionuclides in clinical oncology.
Insights
Researchers developed novel rhenium-188-labeled fibroblast activation protein inhibitor (FAPI) compounds. These 188Re-FAPI probes offer a cost-effective and effective approach for FAP-targeted radionuclide therapy in cancer treatment.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Chemistry
- Oncology
Background:
- Fibroblast activation protein (FAP) is a key target for cancer theranostics.
- Optimizing FAP-targeted radiopharmaceuticals is crucial for effective cancer therapy.
- Rhenium-188 (188Re) is a theranostic radionuclide with therapeutic and imaging capabilities.
Purpose of the Study:
- To develop and evaluate novel 188Re-labeled fibroblast activation protein inhibitor (FAPI) compounds.
- To explore cost-effective alternatives for FAP-targeted radionuclide therapy (FAP-TRT).
- To enhance the efficacy and clinical translation of FAP-targeted therapies.
Main Methods:
- Rational structure optimization of FAPI probes.
- Conjugation of FAPI probes with the radionuclide 188Re.
- Evaluation of the developed 188Re-labeled FAPI compounds for cancer theranostics.
Main Results:
- Four novel 188Re-labeled FAPI compounds were successfully developed and evaluated.
- These compounds demonstrated potential as viable alternatives to existing therapeutic radionuclides.
- The study highlights the promise of 188Re-FAPI for FAP-targeted radionuclide therapy.
Conclusions:
- 188Re-labeled FAPI compounds represent a promising strategy for advancing FAP-targeted cancer theranostics.
- This approach offers a cost-effective solution for clinical oncology.
- Further development of these agents could significantly impact cancer treatment outcomes.
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
